Linda Mellby
Laboratory Director
recombinant antibody
immunovia
Sweden
Biography
Linda has more than 10 years experiences of recombinant antibody microarray technology, the Immunovia platform, she has deep knowledge about platform features, technology development as well as clinical applications within oncoproteomics and autoimmunity. She has been one of the key researchers managing the development of the Immunovia antibody microarray platform for disease proteomics, conducting extensive work related to process optimizations, standardizations as well as clinical studies. Linda Mellby received her Ph.D. in Immunotechnology from Dept. of Immunotechnology within CREATE Health Translational Cancer Center, Lund University, in 2010, and a MSc in Chemistry Engineering in 2004.
Research Interest
recombinant antibody microarray technology
